PCC has initiated a new and exciting project with strategy consulting and market intelligence specialists DeciBio, which has now successfully completed phase 1, culminating in a productive and insightful face-to-face workshop at ASCO in June.  The project aims to reveal insights into the adoption of liquid biopsy testing and find solutions for under-served populations. Read more about this project here and look out for the publication of phase 2 findings later this year.

NGS is a diagnostic technology that rapidly sequences DNA and simultaneously tests for multiple genetic anomalies. NGS offers advantages over sequential SGT by providing faster results and may be more cost-effective overall.